Serum chromogranin A in the diagnosis and follow‐up of neuroendocrine tumors of the gastroenteropancreatic tract
The DOI matches its Crossref record.
Abstract
Hormonally active neuroendocrine tumors may easily be diagnosed by elevated serum levels of their specific peptides and hormonal products, but there are no reliable markers for neuroendocrine tumors without hormonal activity. Chromogranin A (CgA), a secretory protein of neuroendocrine cells, has recently been characterized as a valuable tissue marker in hormonally active and non‐functioning neuroendocrine tumors. This study analyzes the role of CgA as a serum marker for different neuroendocrine tumors. Thirty‐three patients with neuroendocrine tumors of the stomach (n=7), the ileum (n=18), and the pancreas (n=8) were investigated. Serum CgA levels were analyzed by radioimmunoassay at the time of diagnosis and during follow‐up under different therapeutic regimens. Serum CgA was elevated in 30 (91%) patients. Mean CgA serum levels varied with tumor location (pancreas: 7068±3008 ng/ml, ileum: 5381±1740 ng/ml, stomach: 529±179 ng/ml, x±SEM ng/ml) but did not differ between functioning and non‐functioning tumors. Eight of 10 patients treated with either somatostatin or interfer‐on‐alpha showed changes of CgA concentrations corresponding to tumor growth. We conclude that CgA is a useful broad‐spectrum tumor marker in gastroenteropancreatic neuroendocrine tumors. Its determination is especially recommended in tumors without hormonal activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels, Kwekkeboom, Bouillon, & Lamberts (1998) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1998.00305.x · Cited by 151
Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
“Sensitivity of CgA as a marker of neuroendocrine gastro-entero-pancreatic tumors depends on the location of the original tumor [60, 61], metastatic cancer, especially liver metastases [23, 30, 62, 63], and laboratory methodology: determining cutoff CgA [10, 34, 41, 62] and the use of a particular method for detection…”
MethodBørglum, T., Rehfeld, J. F., Drivsholm, L. B., & Hilsted, L. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076158 · Cited by 42
Library of Sequence-specific Radioimmunoassays for Human Chromogranin A
Børglum Jensen, T., Hilsted, L., & Rehfeld, J. F. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.4.549 · Cited by 33
Metadata
- Authors
- Schürmann, G., Raeth, U., Wiedenmann, B., Buhr, H., & Herfarth, C.
- Venue
- World Journal of Surgery
- Publisher
- Wiley
- Published
- 1992-07
- Volume
- 16
- Issue
- 4
- Pages
- 697-701
- ISSN
- 0364-2313 (ISSN-L)
- 1432-2323
- OpenAlex
- W2083075999
- Cited by
- 49
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.